BBBeth Borowsky

Beth Borowsky

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Beth Borowsky has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Alexandra Durr

    APHP Department of Genetics, Groupe Hospitalier Pitié-Salpêtrière, and Institut du Cerveau et de la Moelle, INSERM U1127, CNRS UMR7225, UPMC Université Paris VI UMR_S1127, Paris France

    2 shared publications
  • Blair R. Leavitt

    University of British Columbia

    2 shared publications
  • Cristina Sampaio

    CHDI Management/CHDI Foundation Princeton New Jersey USA

    2 shared publications
  • Sarah J. Tabrizi

    Huntington’s Disease Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK

    2 shared publications
  • Adeel Razi

    Monash University, Melbourne, Australia

    1 shared publication
  • Allan J. Tobin

    From CHDI Management/CHDI Foundation (B.B., J.W., C.S.), Princeton, NJ; Centre for Molecular Medicine and Therapeutics (B.R.L.), Department of Medical Genetics, University of British Columbia, Vancouver, Canada; UCL Institute of Neurology (S.J.T.), University College London, Queen Square, London, UK; Department of Neurology (R.A.C.R.), Leiden University Medical Centre, Leiden, the Netherlands; Department of Genetics and Cytogenetics (A.D.), UPMC Université Paris 06, UMR S975 Hôpital de la...

    1 shared publication

Latest Publications

  • D22 Compensation in preclinical huntington’s disease: evidence from the track-on HD study

    by Sarah Gregory, Stefan Klöppel, Elisa Scheller, Lora Minkova, Adeel Razi, Alexandra Durr, Raymund Ac Roos, Blair R Leavitt, Marina Papoutsi, G Bernhard Landwehrmeyer, et al.

    Background Cognitive and motor task performance in premanifest Huntington’s disease (HD) gene-carriers is often within normal ranges prior to clinical diagnosis, despite loss of brain volume in regions involved in these tasks. This indicates ongoing compensation, with the brain maintaining function in the presence of neuronal loss. However, thus far, compensatory processes in HD have not been explicitly addressed in statistical models. Aims Using a new statistical model, which incorporates individual variability related to structural burden (i.e., loss of brain volume) and behaviour, we sought to identify functional correlates of compensation in premanifest-HD gene-carriers. Methods We investigated the modulatory effects of regional brain atrophy, indexed by structural measures of disease load, on the relationship between performance and brain activity (or connectivity) using task-based and resting-state functional MRI. Results Consistent with compensation, higher atrophy was associated with increased performance-related activity of the right parietal cortex during a working memory task. Similarly, higher functional coupling between the right dorsolateral prefrontal cortex and a left hemisphere network in the resting-state predicted better cognitive performance in individuals with higher disease burden. Such patterns were not detectable for the left hemisphere or for motor tasks. Conclusion Our findings provide evidence for active compensatory processes in premanifest-HD for cognitive demands and suggest a higher vulnerability of the left hemisphere to the effects of regional atrophy.


  • HD‐CAB: A cognitive assessment battery for clinical trials in Huntington's disease1,2,3

    by Julie C. Stout, Sarah Queller, Kalyca N. Baker, Sean Cowlishaw, Cristina Sampaio, Cheryl Fitzer‐Attas, Beth Borowsky, the HD‐CAB Investigators

    Cognitive dysfunction is central to Huntington's disease (HD) and undermines quality of life. Clinical trials are now targeting cognitive outcomes in HD; however, no cognitive battery has been optimized for HD clinical trials. We evaluated 16 cognitive tests in a 20‐site, five‐country, observational study designed to mimic aspects of a clinical trial (e.g., data collection managed by a contract research organization, repeated testing, prespecified statistical analyses). Fifty‐five early HD, 103 premanifest HD (pre‐HD), and 105 controls were tested at visit 1, visit 2 (1‐3 days later), and visit 3 (5‐7 weeks after visit 1). For inclusion in a recommended battery, tests were evaluated for sensitivity, practice effects, reliability, domain coverage, feasibility, and tolerability. Most tests differentiated controls from pre‐HD and early HD and showed excellent psychometric properties. We selected six tests to constitute the Huntington's Disease Cognitive Assessment Battery (HD‐CAB): Symbol Digit Modalities Test, Paced Tapping, One Touch Stockings of Cambridge (abbreviated), Emotion Recognition, Trail Making B, and the Hopkins Verbal Learning Test. These tests demonstrated sensitivity to disease status (Cohen's d effect sizes: early HD= −1.38 to −1.90 and pre‐HD= −0.41 to −0.78), and acceptable reliability (r's 0.73‐0.93). A composite score yielded large effect sizes (early HD = −2.44 and pre‐HD = −0.87) and high reliability (r = 0.95). HD‐CAB is the first cognitive battery designed specifically for use in late premanifest and early HD clinical trials. Adoption of the HD‐CAB will facilitate evaluation of treatments to improve cognition in HD. © 2014 International Parkinson and Movement Disorder Society


  • 8OHdG is not a biomarker for Huntington disease state or progression

    by Beth Borowsky, John Warner, Blair R. Leavitt, Sarah J. Tabrizi, Raymund A.C. Roos, Alexandra Durr, Chris Becker, Cristina Sampaio, Allan J. Tobin, Howard Schulman

    Objective: To evaluate plasma 8-hydroxy-deoxy-guanosine (8OHdG) levels as a potential biomarker of premanifest and early Huntington disease (HD). Methods: Personnel from 2 independent laboratories quantified 8OHdG in blinded longitudinal plasma samples taken 24 months apart from 160 TRACK-HD participants, as well as samples containing control plasma with added (“spiked”) 8OHdG. One laboratory used a liquid chromatography–electrochemical array (LCECA) assay, and the other used liquid chromatography–mass spectrometry (LCMS). Results: The LCMS assay was more accurate than the LCECA assay for measurements of “spiked” 8OHdG levels in plasma. Neither assay demonstrated cross-sectional differences in plasma 8OHdG among controls, premanifest HD, and early symptomatic HD. Similarly, neither assay showed longitudinal changes in any disease group over 24 months. Conclusions: Plasma concentration of 8OHdG is not a biomarker of disease state or progression in HD. We recommend that future putative biomarker studies use blinded sample analysis, standard curves, independent analytical methods, and strict quality control of sample collection and storage.